Zachary Roberts
Chief Tech/Sci/R&D Officer presso ALLOGENE THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Zachary Roberts is currently the Chief Medical Officer & Executive Vice President at Allogene Therapeutics, Inc. He previously worked as the Director-Clinical Medical Research at Amgen, Inc. in 2015, the Vice President-Clinical Development at Kite Pharma, Inc. from 2018 to 2019, and the Chief Medical Officer at Instil Bio, Inc. from 2020 to 2022.
Dr. Roberts obtained his undergraduate degree from the University of Maryland and his doctorate from the University of Maryland School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 25/01/2024 | 515 253 ( 0.30% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Zachary Roberts
| Società | Posizione | Inizio |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 03/01/2023 |
Precedenti posizioni note di Zachary Roberts
| Società | Posizione | Fine |
|---|---|---|
| INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 11/11/2022 |
| KITE PHARMA INC | Chief Tech/Sci/R&D Officer | 01/05/2019 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/07/2015 |
Formazione di Zachary Roberts
| University of Maryland | Undergraduate Degree |
| University of Maryland School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
- Borsa valori
- Insiders
- Zachary Roberts
